Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric inebilizumab PK/PD and safety study in NMOSD
2021-003528-33Phase 2Active
- Sponsor
- Horizon Therapeutics
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD), sponsored by Horizon Therapeutics. Primary endpoint: Pharmacokinetic parameters. Started Mar 2022; status: active.
02
Drugs
inebilizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on 2021-003528-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003528-33.